Search clinical trials for: disease modifying drugs

Total 435309 results

Novartis Pharmaceuticals

Completed

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (PASSAGE)

Multiple Sclerosis

United States, Australia, Canada, Mexico, Argentina, Puerto Rico, Chile
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Pfizer

Completed

Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
AbbVie

Completed

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

Rheumatoid Arthritis (RA)

Brazil, China, Korea, Republic of
Hospital Universitario Ramon y Cajal

Terminated

Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01) (COVITOZ-01)

Covid19

Spain
Jawaharlal Institute of Postgraduate Medical Education...

Terminated

Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy

Rheumatoid Arthritis

India
Hoffmann-La Roche

Completed

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (HIBISCUS I)

Ulcerative Colitis

United States, Australia, Serbia, Hong Kong, Brazil, Bulgaria, Estonia, Poland, Russian Federation, Mexico, Ukraine, Argentina, France, Slovakia
University of Reading
Volac International Limited

Completed

Modifying Whey Protein Fortified Drinks and Foods

Individual Difference | Food Preferences | Food Sensitivity

United Kingdom
Gilead Sciences
Galapagos NV

Completed

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment (FINCH 2)

Rheumatoid Arthritis

United States, France, Germany, Spain, Israel, Japan, Korea, Republic of, Belgium, Argentina, Poland, Hungary, United Kingdom, Mexico, Australia, Switzerland
Hikma Pharmaceuticals LLC

Completed

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Inflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | Fistulizing Crohn's Disease

Saudi Arabia
Duke University
Patient-Centered Outcomes Research Institute; Beth Israel Deaconess Medical...

Completed

Disease-Modifying Treatments for Myasthenia Gravis (PROMISE-MG)

Autoimmune Diseases | Neurological Disorder

United States, Canada
Gilead Sciences
Galapagos NV

Withdrawn

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy (SEALION1-IR)

Ankylosing Spondylitis
Gilead Sciences
Galapagos NV

Withdrawn

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy (SEALION2-NAÏVE)

Ankylosing Spondylitis
GlaxoSmithKline
Parexel

Completed

Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

Germany, United States, Poland
Novartis Pharmaceuticals

Completed

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. (PREFERMS)

Relapsing Remitting Multiple Sclerosis

United States, Puerto Rico
Eisai Korea Inc.

Completed

Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World (HUMAN)

Arthritis, Rheumatoid

Korea, Republic of
Columbia University
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Completed

RHYTHM (Formerly Escape II Myocardium) (RHYTHM)

Rheumatoid Arthritis

United States
Rennes University Hospital

Completed

Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS) (COPP-MS)

Multiple Sclerosis

France
Singapore General Hospital

Completed

A Musculoskeletal Ultrasound Program to Improve Disease Modifying Anti-Rheumatic Drugs Adherence in Rheumatoid Arthritis

Rheumatoid Arthritis

Singapore
University Hospital, Caen
Genzyme, a Sanofi Company; Ligue contre le cancer, France

Completed

Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration (PREMISEP)

C10.114.375.500

France
Pfizer

Completed

Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions

Arthritis, Rheumatoid

Colombia, Peru
Fundación Santa Fe de Bogota

Unknown

Predictive Factors for COVID-19 in Rheumatology

Covid19 | Rheumatic Diseases
UCB Pharma
National Data Bank for Rheumatic Diseases (NDB)

Completed

National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)

Rheumatoid Arthritis
Genentech, Inc.

Completed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Hypercholesterolemia

United States, France, Italy, Germany, Spain, Canada, United Kingdom, Australia, Mexico
Hikma Pharmaceuticals LLC
Syneos Health

Completed

Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan (PASSRRA)

Rheumatoid Arthritis

Jordan
Daiichi Sankyo, Inc.

Completed

AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment (DESIRABLE)

Rheumatoid Arthritis

Japan
Janssen Research & Development, LLC

Completed

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Hepatitis C, Chronic

Poland, Belgium, Germany, Spain, Canada, Singapore
Vanderbilt University Medical Center

Completed

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study (MIND-USA)

Delirium | Impaired Cognition | Long Term Psychologic Disorders

United States
Jawaharlal Institute of Postgraduate Medical Education...

Completed

Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis

Rheumatoid Arthritis

India
Nanfang Hospital of Southern Medical University

Unknown

Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs

Ankylosing Spondylitis | Spondyloarthritis

China
Sanofi
Regeneron Pharmaceuticals

Completed

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Hypercholesterolaemia

United States
University of Leeds

Completed

Very Early Versus Delayed Etanercept in Patients With RA (VEDERA)

Rheumatoid Arthritis

United Kingdom
Nanfang Hospital of Southern Medical University

Completed

Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS

Ankylosing Spondylitis

China
Hoffmann-La Roche

Completed

EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

Rheumatoid Arthritis

Greece
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Novartis Pharmaceuticals

Completed

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (EARLiMS)

Relapsing Remitting Multiple Sclerosis

Spain, Australia
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin (ODYSSEY-NIPPON)

Hypercholesterolemia

Japan
Celgene

Terminated

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Breast Neoplasms

Spain, United States, Belgium, Italy, France, Germany
Hoffmann-La Roche

Completed

A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Greece
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy (TOSCA)

Rheumatoid Arthritis

France
Incyte Corporation

Completed

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

Rheumatoid Arthritis

United States, Czechia
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs) (TREASURE)

Rheumatoid Arthritis

Korea, Republic of
UCB Pharma

Completed

Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, United Kingdom, Belgium, Germany, Austria, Ireland, Czechia
UCB Pharma

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

Rheumatoid Arthritis

Germany, United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, France, Hungary, Ireland, Italy, Mexico, Monaco, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
UCB Pharma SA

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

Rheumatoid Arthritis

Germany, United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, France, Hungary, Ireland, Italy, Mexico, Monaco, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Open Label Study of Long Term Safety Evaluation of Alirocumab (ODYSSEY OLE)

Hypercholesterolemia

United States, Argentina, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Portugal, Romania, Russian Federation, South Africa, Spain, Sweden, United...
Yonsei University

Completed

Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia

Hyperlipidemia

Korea, Republic of
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Hypercholesterolaemia

Belgium, Spain, Germany, Austria, Italy, United States, France, Netherlands, Switzerland, United Kingdom

3

Subscribe